New 'See and Treat' approach targets Hard-to-Treat prostate cancer

NCT ID NCT04868604

Recruiting now Disease control Sponsor: Clarity Pharmaceuticals Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two copper-based drugs that work together: one helps doctors see prostate cancer tumors on scans, and the other delivers targeted radiation to kill them. The trial involves 54 men with a type of advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest and most effective dose while checking if the treatment can shrink tumors or lower PSA levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA (copper-based imaging and therapy agents)
What this could lead to: If successful, this could lead to a more targeted way to both detect and treat advanced prostate cancer with fewer side effects than traditional therapies.
What could go wrong: This is an early-phase trial with only 54 participants, so results may not apply to all patients. The therapy may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS, CASTRATION-RESISTANT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

BAMF Health
RECRUITING

Grand Rapids, Michigan, 49503, United States

Contact
East Jefferson General Hospital
RECRUITING

River Ridge, Louisiana, 70123, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

Contact
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States

Contact

Contact
Washington University School of Medicine at Barnes-Jewish Hospital
RECRUITING

St Louis, Missouri, 63110, United States

Contact
Weill Cornell Medicine at New York-Presbyterian
RECRUITING

New York, New York, 10021, United States

Contact
XCancer
RECRUITING

Omaha, Nebraska, 68130, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.